Clinical Trial Update: Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing concurrent versus sequential sipuleucel-T and abiraterone in metastatic castration-resistant prostate cancer has completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Hormone-refractory Prostate Cancer
• Prostate Cancer Metastatic

Drugs mentioned

• Abiraterone (abiraterone)
• sipuleucel-T (sipuleucel-T)

Snippet

Sponsor: Dendreon | Conditions: Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-06-12